Skip to main content
. 2018 Mar 5;7(1):173–183. doi: 10.1007/s40123-018-0123-0

Table 1.

Patient demographics and baseline characteristics of the DMO cohort

Patient demographics
Participants, n 13
Number of eyes, n 18
Male, n (%) 11 (85%)
Right eyes, n (%) 8 (44%)
Age (years) 68 ± 6.6
Baseline BCVA, number of letters 61.5 ± 13.8
Baseline CMT (µm) 433.2 ± 101.4
Total previous bevacizumab injections, n 7 ± 5.6
Number bevacizumab injections in preceding 6 months, n 1.8 ± 1.5
Total previous ranibizumab injections, n 4.3 ± 4.4
Number ranibizumab injections in preceding 6 months, n 1.2 ± 1.5
Total intravitreal injections (IVI) pre-switch, n 11.3 ± 7.2
Total IVI previous 6 months, n 3
Follow-up (months) 22.5 ± 7.9

Data expressed as mean ± SD

SD standard deviation, DMO diabetic macular oedema, BCVA best corrected visual acuity, CMT central macular thickness, IVI intravitreal injections

HHS Vulnerability Disclosure